



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

October 2018





HIV/AIDS Drug Treatment Program

Monthly Report

© 2018 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

October 2018

N = 7338



| Health Authority | Male | Female | All |
|-------------------|-------------|----------------------------|-------------|
| FRASER | 1434 | 415 | 1849 |
| INTERIOR | 380 | 98 | 478 |
| NORTHERN | 128 | 81 | 209 |
| VANCOUVER COASTAL | 3418 | 459 | 3877 |
| VANCOUVER ISLAND | 739 | 145 | 884 |
| | 6099 | 1198 | 7297 |
| | | Unknown/not stated: | 41 |
| | | Total: | 7338 |

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (October 2013 - October 2018)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (October 2013 - October 2018)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (October 2013 - October 2018)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (October 2013 - October 2018)






1.6 Percent Distribution of Active Participants by CD4 Count (October 2013 - October 2018)






1.7 Percent Distribution of Inactive Participants by CD4 Count
(October 2013 - October 2018)






1.8 Active and Inactive Participants (October 2013 - October 2018)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (October 2013 - October 2018)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (October 2013 - October 2018)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(October 2013 - October 2018)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (October 2013 - October 2018)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(October 2013 - October 2018)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (October 2013 - October 2018)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(October 2013 - October 2018)





1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (October 2013 - October 2018)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(October 2013 - October 2018)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes






1.18 Baseline CD4 for Antiretroviral First Starts (October 2013 - October 2018)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(October 2013 - October 2018)**






1.20 Cumulative Resistance Testing Results by Resistance Category (October 2013 - October 2018)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (October 2013 - October 2018)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2018
(for HIV+ persons currently on treatment)**

| Start Year | Duration (years) Median | Male | Female | All | Current CD4 (n) | Median | Current PVL (n) | Median | Current ARV Median |
|---------------|----------------------------|-------------|-------------|-------------|--------------------|--------|--------------------|--------|-----------------------|
| 1987 | 26 | 5 | 0 | 5 | 5 | 760 | 5 | <40 | 3 |
| 1988 | 27 | 7 | 0 | 7 | 7 | 450 | 7 | <40 | 3 |
| 1989 | 25 | 54 | 2 | 56 | 47 | 480 | 53 | <40 | 3 |
| 1990 | 24 | 56 | 1 | 57 | 52 | 520 | 56 | <40 | 3 |
| 1991 | 24 | 38 | 2 | 40 | 31 | 590 | 39 | <40 | 3 |
| 1992 | 24 | 66 | 6 | 72 | 55 | 550 | 70 | <40 | 3 |
| 1993 | 23 | 140 | 16 | 156 | 146 | 555 | 155 | <40 | 3 |
| 1994 | 22 | 81 | 10 | 91 | 79 | 570 | 89 | <40 | 3 |
| 1995 | 22 | 130 | 22 | 152 | 126 | 555 | 146 | <40 | 3 |
| 1996 | 20 | 364 | 58 | 422 | 367 | 580 | 409 | <40 | 3 |
| 1997 | 18 | 296 | 35 | 331 | 292 | 630 | 318 | <40 | 3 |
| 1998 | 17 | 209 | 46 | 255 | 215 | 560 | 244 | <40 | 3 |
| 1999 | 17 | 165 | 41 | 206 | 175 | 560 | 191 | <40 | 3 |
| 2000 | 17 | 125 | 34 | 159 | 136 | 590 | 149 | <40 | 3 |
| 2001 | 17 | 124 | 32 | 156 | 134 | 570 | 147 | <40 | 3 |
| 2002 | 16 | 130 | 26 | 156 | 129 | 580 | 150 | <40 | 3 |
| 2003 | 15 | 160 | 29 | 189 | 162 | 615 | 184 | <40 | 3 |
| 2004 | 14 | 168 | 42 | 210 | 174 | 595 | 198 | <40 | 3 |
| 2005 | 13 | 187 | 47 | 234 | 208 | 630 | 223 | <40 | 3 |
| 2006 | 12 | 196 | 37 | 233 | 195 | 590 | 222 | <40 | 3 |
| 2007 | 11 | 262 | 48 | 310 | 262 | 600 | 293 | <40 | 3 |
| 2008 | 10 | 298 | 67 | 365 | 304 | 655 | 347 | <40 | 3 |
| 2009 | 9 | 329 | 71 | 400 | 346 | 640 | 376 | <40 | 3 |
| 2010 | 8 | 290 | 70 | 360 | 309 | 660 | 336 | <40 | 3 |
| 2011 | 7 | 330 | 74 | 404 | 351 | 670 | 385 | <40 | 3 |
| 2012 | 6 | 287 | 61 | 348 | 302 | 700 | 336 | <40 | 3 |
| 2013 | 5 | 282 | 66 | 348 | 291 | 666 | 328 | <40 | 3 |
| 2014 | 4 | 295 | 48 | 343 | 279 | 710 | 322 | <40 | 3 |
| 2015 | 3 | 296 | 50 | 346 | 281 | 660 | 320 | <40 | 3 |
| 2016 | 2 | 290 | 60 | 350 | 291 | 630 | 327 | <40 | 3 |
| 2017 | 1 | 247 | 43 | 290 | 251 | 630 | 278 | <40 | 3 |
| 2018 | 0 | 207 | 54 | 261 | 233 | 570 | 251 | <40 | 3 |
| Total: | | 6114 | 1198 | 7312 | | | | | |

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

| MON-YYYY | # of patients | Median # of therapy days | # of patients with PVL test | Median PVL | # of patients with CD4 test | Median CD4 |
|----------|---------------|--------------------------|-----------------------------|------------|-----------------------------|------------|
| JAN-2017 | 7182 | 747 | 2326 | <40 | 2077 | 590 |
| FEB-2017 | 7134 | 754 | 1914 | <40 | 1739 | 590 |
| MAR-2017 | 7186 | 744 | 2204 | <40 | 2018 | 600 |
| APR-2017 | 7178 | 746 | 1966 | <40 | 1770 | 590 |
| MAY-2017 | 7224 | 744 | 2275 | <40 | 2058 | 590 |
| JUN-2017 | 7245 | 752 | 2120 | <40 | 1953 | 596 |
| JUL-2017 | 7241 | 753 | 1964 | <40 | 1789 | 580 |
| AUG-2017 | 7266 | 757 | 2106 | <40 | 1884 | 590 |
| SEP-2017 | 7222 | 762 | 2042 | <40 | 1837 | 610 |
| OCT-2017 | 7244 | 770 | 2186 | <40 | 1937 | 610 |
| NOV-2017 | 7240 | 766 | 2073 | <40 | 1872 | 610 |
| DEC-2017 | 7227 | 775 | 1739 | <40 | 1536 | 610 |
| JAN-2018 | 7293 | 755 | 2385 | <40 | 2102 | 610 |
| FEB-2018 | 7256 | 765 | 1904 | <40 | 1741 | 610 |
| MAR-2018 | 7278 | 774 | 2049 | <40 | 1824 | 610 |
| APR-2018 | 7265 | 781 | 2082 | <40 | 1839 | 620 |
| MAY-2018 | 7288 | 780 | 2149 | <40 | 1922 | 600 |
| JUN-2018 | 7294 | 795 | 2009 | <40 | 1781 | 610 |
| JUL-2018 | 7298 | 797 | 2038 | <40 | 1788 | 600 |
| AUG-2018 | 7300 | 801 | 2092 | <40 | 1835 | 610 |
| SEP-2018 | 7259 | 803 | 2016 | <40 | 1692 | 630 |
| OCT-2018 | 7338 | 784 | 2168 | <40 | 1853 | 610 |

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

| MON-YYYY | # of patients | Median # days of off therapy | # of patients with PVL test | Median PVL | # of patients with CD4 test | Median CD4 |
|----------|---------------|------------------------------|-----------------------------|------------|-----------------------------|------------|
| JAN-2017 | 1402 | 3157 | 88 | 140 | 80 | 417 |
| FEB-2017 | 1455 | 2851 | 80 | 1874 | 70 | 400 |
| MAR-2017 | 1408 | 3137 | 99 | 635 | 89 | 380 |
| APR-2017 | 1423 | 3092 | 94 | 545 | 85 | 420 |
| MAY-2017 | 1394 | 3284 | 85 | 180 | 75 | 420 |
| JUN-2017 | 1384 | 3368 | 76 | 197 | 69 | 480 |
| JUL-2017 | 1404 | 3259 | 67 | 436 | 60 | 500 |
| AUG-2017 | 1397 | 3352 | 78 | 160 | 68 | 495 |
| SEP-2017 | 1454 | 3064 | 74 | 323 | 66 | 415 |
| OCT-2017 | 1428 | 3244 | 91 | 218 | 80 | 470 |
| NOV-2017 | 1448 | 3135 | 80 | 133 | 69 | 370 |
| DEC-2017 | 1478 | 3043 | 60 | 53 | 50 | 382 |
| JAN-2018 | 1430 | 3299 | 78 | 872 | 70 | 365 |
| FEB-2018 | 1476 | 3102 | 79 | 1036 | 65 | 450 |
| MAR-2018 | 1462 | 3168 | 75 | 59 | 70 | 485 |
| APR-2018 | 1480 | 3139 | 72 | 634 | 61 | 500 |
| MAY-2018 | 1462 | 3229 | 91 | <40 | 82 | 455 |
| JUN-2018 | 1469 | 3234 | 67 | 4210 | 61 | 410 |
| JUL-2018 | 1474 | 3255 | 68 | <40 | 54 | 555 |
| AUG-2018 | 1506 | 3143 | 64 | 56 | 53 | 480 |
| SEP-2018 | 1548 | 2983 | 88 | 164 | 77 | 410 |
| OCT-2018 | 1493 | 3255 | 83 | <40 | 69 | 380 |

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

| MON-YYYY | Currently on ARV Therapy | Currently off ARV Therapy | Deceased | First Starts | Experienced Starts | New Inactive | Net Change | Cumulative Patients |
|----------|--------------------------|---------------------------|----------|--------------|--------------------|--------------|------------|---------------------|
| JAN-2017 | 7140 | 1402 | 21 | 21 | 141 | 142 | -6 | 12876 |
| FEB-2017 | 7102 | 1455 | 10 | 24 | 136 | 182 | -38 | 12910 |
| MAR-2017 | 7147 | 1408 | 17 | 19 | 189 | 139 | 45 | 12936 |
| APR-2017 | 7139 | 1423 | 12 | 20 | 143 | 151 | -8 | 12968 |
| MAY-2017 | 7194 | 1394 | 7 | 22 | 170 | 126 | 55 | 13002 |
| JUN-2017 | 7209 | 1384 | 10 | 24 | 151 | 138 | 15 | 13032 |
| JUL-2017 | 7202 | 1404 | 7 | 14 | 134 | 142 | -7 | 13051 |
| AUG-2017 | 7229 | 1397 | 10 | 25 | 156 | 137 | 27 | 13081 |
| SEP-2017 | 7185 | 1454 | 12 | 16 | 137 | 180 | -44 | 13110 |
| OCT-2017 | 7212 | 1428 | 7 | 6 | 184 | 151 | 27 | 13123 |
| NOV-2017 | 7205 | 1448 | 16 | 19 | 142 | 149 | -7 | 13158 |
| DEC-2017 | 7197 | 1478 | 5 | 18 | 158 | 175 | -8 | 13189 |
| JAN-2018 | 7253 | 1430 | 13 | 12 | 192 | 127 | 56 | 13218 |
| FEB-2018 | 7220 | 1476 | 11 | 27 | 123 | 169 | -33 | 13255 |
| MAR-2018 | 7238 | 1462 | 17 | 21 | 152 | 134 | 18 | 13282 |
| APR-2018 | 7230 | 1480 | 13 | 15 | 153 | 159 | -8 | 13304 |
| MAY-2018 | 7259 | 1462 | 9 | 12 | 171 | 143 | 29 | 13329 |
| JUN-2018 | 7258 | 1469 | 13 | 16 | 149 | 150 | -1 | 13351 |
| JUL-2018 | 7258 | 1474 | 13 | 14 | 156 | 152 | 0 | 13377 |
| AUG-2018 | 7269 | 1506 | 9 | 27 | 156 | 160 | 11 | 13416 |
| SEP-2018 | 7230 | 1548 | 16 | 15 | 153 | 188 | -39 | 13442 |
| OCT-2018 | 7312 | 1493 | 7 | 19 | 216 | 142 | 82 | 13478 |

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

| MON-YYYY | Less than 3 Drugs | 3 Drugs | 4 Drugs | 5 or more Drugs | All ARV | Less than 3 Drugs% | 3 Drugs% | 4 Drugs% | 5 or more Drugs% | Total% |
|----------|-------------------|---------|---------|-----------------|-------------|--------------------|----------|----------|------------------|----------------|
| JAN-2017 | 61 | 6615 | 443 | 63 | 7182 | 0.85% | 92.11% | 6.17% | 0.88% | 100.00% |
| FEB-2017 | 60 | 6579 | 440 | 55 | 7134 | 0.84% | 92.22% | 6.17% | 0.77% | 100.00% |
| MAR-2017 | 60 | 6629 | 439 | 58 | 7186 | 0.83% | 92.25% | 6.11% | 0.81% | 100.00% |
| APR-2017 | 58 | 6633 | 428 | 59 | 7178 | 0.81% | 92.41% | 5.96% | 0.82% | 100.00% |
| MAY-2017 | 62 | 6665 | 438 | 59 | 7224 | 0.86% | 92.26% | 6.06% | 0.82% | 100.00% |
| JUN-2017 | 57 | 6691 | 438 | 59 | 7245 | 0.79% | 92.35% | 6.05% | 0.81% | 100.00% |
| JUL-2017 | 61 | 6685 | 433 | 62 | 7241 | 0.84% | 92.32% | 5.98% | 0.86% | 100.00% |
| AUG-2017 | 61 | 6696 | 448 | 61 | 7266 | 0.84% | 92.16% | 6.17% | 0.84% | 100.00% |
| SEP-2017 | 57 | 6677 | 431 | 57 | 7222 | 0.79% | 92.45% | 5.97% | 0.79% | 100.00% |
| OCT-2017 | 58 | 6691 | 438 | 57 | 7244 | 0.80% | 92.37% | 6.05% | 0.79% | 100.00% |
| NOV-2017 | 59 | 6680 | 445 | 56 | 7240 | 0.81% | 92.27% | 6.15% | 0.77% | 100.00% |
| DEC-2017 | 58 | 6666 | 447 | 56 | 7227 | 0.80% | 92.24% | 6.19% | 0.77% | 100.00% |
| JAN-2018 | 58 | 6729 | 451 | 55 | 7293 | 0.80% | 92.27% | 6.18% | 0.75% | 100.00% |
| FEB-2018 | 61 | 6685 | 451 | 59 | 7256 | 0.84% | 92.13% | 6.22% | 0.81% | 100.00% |
| MAR-2018 | 62 | 6708 | 453 | 56 | 7279 | 0.85% | 92.16% | 6.22% | 0.77% | 100.00% |
| APR-2018 | 58 | 6700 | 449 | 58 | 7265 | 0.80% | 92.22% | 6.18% | 0.80% | 100.00% |
| MAY-2018 | 62 | 6713 | 455 | 58 | 7288 | 0.85% | 92.11% | 6.24% | 0.80% | 100.00% |
| JUN-2018 | 60 | 6727 | 449 | 58 | 7294 | 0.82% | 92.23% | 6.16% | 0.80% | 100.00% |
| JUL-2018 | 52 | 6730 | 461 | 55 | 7298 | 0.71% | 92.22% | 6.32% | 0.75% | 100.00% |
| AUG-2018 | 53 | 6736 | 455 | 56 | 7300 | 0.73% | 92.27% | 6.23% | 0.77% | 100.00% |
| SEP-2018 | 51 | 6690 | 459 | 59 | 7259 | 0.70% | 92.16% | 6.32% | 0.81% | 100.00% |
| OCT-2018 | 53 | 6754 | 477 | 54 | 7338 | 0.72% | 92.04% | 6.50% | 0.74% | 100.00% |

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

| | lamivudine | | abacavir | | zidovudine | | stavudine | | didanosine | | tenofovir <TAF> | | tenofovir <TDF> | |
|----------|------------|----------|----------|----------|------------|-------|-----------|------|------------|------|-----------------|--------|-----------------|----------|
| | Initial | All | Initial | All | Initial | All | Initial | All | Initial | All | Initial | All | Initial | All |
| JAN-2017 | 13 41% | 3068 44% | 13 41% | 2772 40% | 0 0% | 75 1% | 0 0% | 5 0% | 0 0% | 6 0% | 0 0% | 46 1% | 19 59% | 4051 58% |
| FEB-2017 | 12 35% | 3074 44% | 10 29% | 2783 40% | 1 3% | 71 1% | 0 0% | 5 0% | 0 0% | 6 0% | 0 0% | 50 1% | 22 65% | 3982 58% |
| MAR-2017 | 7 27% | 3105 45% | 7 27% | 2824 41% | 0 0% | 69 1% | 0 0% | 6 0% | 0 0% | 5 0% | 0 0% | 78 1% | 19 73% | 4000 57% |
| APR-2017 | 13 41% | 3114 45% | 12 38% | 2834 41% | 1 3% | 68 1% | 0 0% | 6 0% | 0 0% | 6 0% | 0 0% | 96 1% | 19 59% | 3962 57% |
| MAY-2017 | 9 26% | 3159 45% | 9 26% | 2881 41% | 0 0% | 73 1% | 0 0% | 6 0% | 0 0% | 5 0% | 1 3% | 119 2% | 24 71% | 3930 56% |
| JUN-2017 | 6 20% | 3169 45% | 6 20% | 2902 41% | 0 0% | 71 1% | 0 0% | 6 0% | 0 0% | 5 0% | 2 7% | 143 2% | 22 73% | 3898 55% |
| JUL-2017 | 7 37% | 3198 46% | 7 37% | 2928 42% | 0 0% | 72 1% | 0 0% | 6 0% | 0 0% | 5 0% | 0 0% | 161 2% | 12 63% | 3861 55% |
| AUG-2017 | 6 20% | 3224 46% | 4 13% | 2958 42% | 0 0% | 69 1% | 0 0% | 6 0% | 0 0% | 5 0% | 2 7% | 171 2% | 23 77% | 3838 54% |
| SEP-2017 | 10 34% | 3213 46% | 10 34% | 2950 42% | 0 0% | 66 1% | 0 0% | 5 0% | 0 0% | 4 0% | 3 10% | 207 3% | 16 55% | 3775 54% |
| OCT-2017 | 5 38% | 3241 46% | 5 38% | 2983 42% | 0 0% | 65 1% | 0 0% | 4 0% | 0 0% | 4 0% | 2 15% | 245 3% | 6 46% | 3715 53% |
| NOV-2017 | 9 26% | 3280 47% | 8 23% | 3024 43% | 0 0% | 65 1% | 0 0% | 5 0% | 0 0% | 4 0% | 1 3% | 265 4% | 25 71% | 3661 52% |
| DEC-2017 | 10 32% | 3286 47% | 10 32% | 3032 43% | 0 0% | 64 1% | 0 0% | 5 0% | 0 0% | 4 0% | 1 3% | 272 4% | 22 71% | 3612 52% |
| JAN-2018 | 10 36% | 3320 47% | 9 32% | 3076 43% | 1 4% | 61 1% | 0 0% | 5 0% | 0 0% | 4 0% | 2 7% | 292 4% | 16 57% | 3635 51% |
| FEB-2018 | 13 35% | 3321 47% | 12 32% | 3079 44% | 0 0% | 61 1% | 0 0% | 5 0% | 0 0% | 4 0% | 0 0% | 299 4% | 25 68% | 3586 51% |
| MAR-2018 | 10 37% | 3340 47% | 10 37% | 3104 44% | 0 0% | 60 1% | 0 0% | 4 0% | 0 0% | 4 0% | 0 0% | 311 4% | 17 63% | 3567 50% |
| APR-2018 | 5 23% | 3348 47% | 5 23% | 3116 44% | 0 0% | 56 1% | 0 0% | 3 0% | 0 0% | 4 0% | 2 9% | 333 5% | 15 68% | 3540 50% |
| MAY-2018 | 9 39% | 3356 47% | 8 35% | 3130 44% | 1 4% | 57 1% | 0 0% | 5 0% | 0 0% | 4 0% | 1 4% | 351 5% | 13 57% | 3517 50% |
| JUN-2018 | 6 30% | 3373 48% | 6 30% | 3149 44% | 0 0% | 54 1% | 0 0% | 5 0% | 0 0% | 3 0% | 1 5% | 380 5% | 13 65% | 3487 49% |
| JUL-2018 | 7 28% | 3401 48% | 7 28% | 3178 45% | 0 0% | 51 1% | 0 0% | 5 0% | 0 0% | 3 0% | 4 16% | 398 6% | 14 56% | 3453 49% |
| AUG-2018 | 13 33% | 3401 48% | 14 36% | 3189 45% | 0 0% | 50 1% | 0 0% | 4 0% | 0 0% | 3 0% | 2 5% | 415 6% | 23 59% | 3417 48% |
| SEP-2018 | 4 15% | 3385 48% | 3 12% | 3171 45% | 1 4% | 47 1% | 0 0% | 4 0% | 0 0% | 2 0% | 4 15% | 446 6% | 18 69% | 3376 48% |
| OCT-2018 | 11 31% | 3420 48% | 9 26% | 3208 45% | 1 3% | 48 1% | 0 0% | 3 0% | 0 0% | 2 0% | 0 0% | 478 7% | 25 71% | 3382 47% |

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

| | emtricitabine | | | |
|----------|---------------|-----|------|-----|
| | Initial | | All | |
| JAN-2017 | 19 | 59% | 3828 | 55% |
| FEB-2017 | 22 | 65% | 3771 | 55% |
| MAR-2017 | 19 | 73% | 3803 | 55% |
| APR-2017 | 19 | 59% | 3791 | 55% |
| MAY-2017 | 25 | 74% | 3795 | 54% |
| JUN-2017 | 24 | 80% | 3797 | 54% |
| JUL-2017 | 12 | 63% | 3770 | 54% |
| AUG-2017 | 24 | 80% | 3767 | 53% |
| SEP-2017 | 19 | 66% | 3740 | 53% |
| OCT-2017 | 7 | 54% | 3731 | 53% |
| NOV-2017 | 26 | 74% | 3693 | 53% |
| DEC-2017 | 21 | 68% | 3665 | 52% |
| JAN-2018 | 18 | 64% | 3711 | 52% |
| FEB-2018 | 24 | 65% | 3680 | 52% |
| MAR-2018 | 17 | 63% | 3673 | 52% |
| APR-2018 | 17 | 77% | 3662 | 52% |
| MAY-2018 | 14 | 61% | 3663 | 52% |
| JUN-2018 | 14 | 70% | 3664 | 52% |
| JUL-2018 | 18 | 72% | 3655 | 52% |
| AUG-2018 | 25 | 64% | 3650 | 51% |
| SEP-2018 | 22 | 85% | 3635 | 52% |
| OCT-2018 | 24 | 69% | 3680 | 52% |

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

| | (fos)amprenavir | | atazanavir | | darunavir | | lopinavir | | nelfinavir | | ritonavir | | saquinavir | |
|----------|-----------------|------|------------|----------|-----------|----------|-----------|--------|------------|------|-----------|------|------------|-------|
| | Initial | All | Initial | All | Initial | All | Initial | All | Initial | All | Initial | All | Initial | All |
| JAN-2017 | 0 0% | 9 0% | 2 14% | 1558 50% | 12 86% | 1313 42% | 0 0% | 247 8% | 0 0% | 3 0% | 0 0% | 1 0% | 0 0% | 12 0% |
| FEB-2017 | 0 0% | 9 0% | 3 19% | 1518 49% | 12 75% | 1307 43% | 1 6% | 236 8% | 0 0% | 3 0% | 0 0% | 1 0% | 0 0% | 12 0% |
| MAR-2017 | 0 0% | 8 0% | 1 8% | 1513 49% | 11 92% | 1329 43% | 0 0% | 232 8% | 0 0% | 2 0% | 0 0% | 1 0% | 0 0% | 12 0% |
| APR-2017 | 0 0% | 8 0% | 0 0% | 1484 49% | 5 71% | 1318 43% | 2 29% | 231 8% | 0 0% | 2 0% | 0 0% | 1 0% | 0 0% | 11 0% |
| MAY-2017 | 0 0% | 9 0% | 0 0% | 1462 48% | 14 100% | 1350 44% | 0 0% | 227 7% | 0 0% | 3 0% | 0 0% | 1 0% | 0 0% | 11 0% |
| JUN-2017 | 0 0% | 9 0% | 2 18% | 1453 48% | 9 82% | 1359 45% | 0 0% | 221 7% | 0 0% | 3 0% | 0 0% | 1 0% | 0 0% | 11 0% |
| JUL-2017 | 0 0% | 9 0% | 0 0% | 1439 47% | 6 100% | 1359 45% | 0 0% | 218 7% | 0 0% | 3 0% | 0 0% | 1 0% | 0 0% | 11 0% |
| AUG-2017 | 0 0% | 9 0% | 1 5% | 1417 47% | 21 95% | 1396 46% | 0 0% | 216 7% | 0 0% | 2 0% | 0 0% | 1 0% | 0 0% | 11 0% |
| SEP-2017 | 0 0% | 9 0% | 0 0% | 1388 46% | 8 100% | 1389 46% | 0 0% | 210 7% | 0 0% | 2 0% | 0 0% | 1 0% | 0 0% | 11 0% |
| OCT-2017 | 0 0% | 8 0% | 0 0% | 1364 46% | 6 100% | 1396 47% | 0 0% | 207 7% | 0 0% | 3 0% | 0 0% | 1 0% | 0 0% | 11 0% |
| NOV-2017 | 0 0% | 8 0% | 1 8% | 1324 45% | 10 83% | 1392 48% | 1 8% | 205 7% | 0 0% | 3 0% | 0 0% | 1 0% | 0 0% | 10 0% |
| DEC-2017 | 0 0% | 7 0% | 1 7% | 1295 45% | 14 93% | 1397 48% | 0 0% | 197 7% | 0 0% | 2 0% | 0 0% | 1 0% | 0 0% | 10 0% |
| JAN-2018 | 0 0% | 8 0% | 3 30% | 1318 45% | 7 70% | 1418 48% | 0 0% | 196 7% | 0 0% | 1 0% | 0 0% | 1 0% | 0 0% | 10 0% |
| FEB-2018 | 0 0% | 6 0% | 0 0% | 1258 44% | 15 100% | 1422 49% | 0 0% | 190 7% | 0 0% | 2 0% | 0 0% | 1 0% | 0 0% | 11 0% |
| MAR-2018 | 0 0% | 7 0% | 1 9% | 1247 43% | 10 91% | 1439 50% | 0 0% | 188 7% | 0 0% | 2 0% | 0 0% | 1 0% | 0 0% | 11 0% |
| APR-2018 | 0 0% | 6 0% | 0 0% | 1223 43% | 11 100% | 1437 50% | 0 0% | 182 6% | 0 0% | 2 0% | 0 0% | 1 0% | 0 0% | 11 0% |
| MAY-2018 | 0 0% | 7 0% | 0 0% | 1210 43% | 5 100% | 1443 51% | 0 0% | 181 6% | 0 0% | 2 0% | 0 0% | 1 0% | 0 0% | 10 0% |
| JUN-2018 | 0 0% | 7 0% | 1 8% | 1191 42% | 11 92% | 1436 51% | 0 0% | 177 6% | 0 0% | 1 0% | 0 0% | 1 0% | 0 0% | 10 0% |
| JUL-2018 | 0 0% | 7 0% | 2 20% | 1171 42% | 7 70% | 1444 52% | 1 10% | 170 6% | 0 0% | 1 0% | 0 0% | 1 0% | 0 0% | 10 0% |
| AUG-2018 | 0 0% | 7 0% | 5 31% | 1157 42% | 11 69% | 1427 52% | 0 0% | 166 6% | 0 0% | 1 0% | 0 0% | 1 0% | 0 0% | 8 0% |
| SEP-2018 | 0 0% | 7 0% | 1 14% | 1134 42% | 6 86% | 1412 52% | 0 0% | 160 6% | 0 0% | 1 0% | 0 0% | 1 0% | 0 0% | 10 0% |
| OCT-2018 | 0 0% | 7 0% | 3 17% | 1123 41% | 15 83% | 1449 53% | 0 0% | 154 6% | 0 0% | 0 0% | 0 0% | 1 0% | 0 0% | 9 0% |

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

| | tipranavir | | | |
|----------|------------|----|-----|----|
| | Initial | | All | |
| JAN-2017 | 0 | 0% | 1 | 0% |
| FEB-2017 | 0 | 0% | 1 | 0% |
| MAR-2017 | 0 | 0% | 1 | 0% |
| APR-2017 | 0 | 0% | 1 | 0% |
| MAY-2017 | 0 | 0% | 1 | 0% |
| JUN-2017 | 0 | 0% | 1 | 0% |
| JUL-2017 | 0 | 0% | 1 | 0% |
| AUG-2017 | 0 | 0% | 1 | 0% |
| SEP-2017 | 0 | 0% | 1 | 0% |
| OCT-2017 | 0 | 0% | 1 | 0% |
| NOV-2017 | 0 | 0% | 1 | 0% |
| DEC-2017 | 0 | 0% | 1 | 0% |
| JAN-2018 | 0 | 0% | 1 | 0% |
| FEB-2018 | 0 | 0% | 1 | 0% |
| MAR-2018 | 0 | 0% | 1 | 0% |
| APR-2018 | 0 | 0% | 1 | 0% |
| MAY-2018 | 0 | 0% | 1 | 0% |
| JUN-2018 | 0 | 0% | 1 | 0% |
| JUL-2018 | 0 | 0% | 1 | 0% |
| AUG-2018 | 0 | 0% | 1 | 0% |
| SEP-2018 | 0 | 0% | 1 | 0% |
| OCT-2018 | 0 | 0% | 1 | 0% |

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

| | efavirenz | | etravirine | | nevirapine | | rilpivirine | |
|----------|-----------|---------|------------|---------|------------|---------|-------------|---------|
| | Initial | All | Initial | All | Initial | All | Initial | All |
| JAN-2017 | 4 80% | 928 41% | 0 0% | 292 13% | 1 20% | 799 35% | 0 0% | 269 12% |
| FEB-2017 | 4 80% | 907 40% | 0 0% | 280 12% | 0 0% | 791 35% | 1 20% | 266 12% |
| MAR-2017 | 1 50% | 897 40% | 0 0% | 279 13% | 0 0% | 790 35% | 1 50% | 265 12% |
| APR-2017 | 4 44% | 888 40% | 0 0% | 273 12% | 1 11% | 787 36% | 4 44% | 271 12% |
| MAY-2017 | 3 75% | 877 40% | 0 0% | 274 12% | 0 0% | 783 35% | 1 25% | 279 13% |
| JUN-2017 | 3 100% | 853 39% | 0 0% | 270 12% | 0 0% | 782 36% | 0 0% | 288 13% |
| JUL-2017 | 2 100% | 838 39% | 0 0% | 264 12% | 0 0% | 779 36% | 0 0% | 283 13% |
| AUG-2017 | 1 100% | 821 38% | 0 0% | 268 12% | 0 0% | 777 36% | 0 0% | 285 13% |
| SEP-2017 | 4 50% | 808 38% | 0 0% | 264 12% | 1 13% | 774 36% | 3 38% | 296 14% |
| OCT-2017 | 1 100% | 802 38% | 0 0% | 267 13% | 0 0% | 768 36% | 0 0% | 299 14% |
| NOV-2017 | 5 71% | 800 38% | 0 0% | 269 13% | 0 0% | 767 36% | 2 29% | 300 14% |
| DEC-2017 | 3 75% | 793 38% | 0 0% | 263 12% | 0 0% | 758 36% | 1 25% | 301 14% |
| JAN-2018 | 3 50% | 779 37% | 1 17% | 263 13% | 2 33% | 757 36% | 0 0% | 302 14% |
| FEB-2018 | 3 75% | 771 37% | 0 0% | 257 12% | 0 0% | 749 36% | 1 25% | 306 15% |
| MAR-2018 | 1 33% | 758 37% | 0 0% | 250 12% | 0 0% | 736 36% | 2 67% | 311 15% |
| APR-2018 | 1 50% | 746 37% | 0 0% | 245 12% | 0 0% | 731 36% | 1 50% | 318 16% |
| MAY-2018 | 4 67% | 725 36% | 1 17% | 252 12% | 0 0% | 727 36% | 1 17% | 316 16% |
| JUN-2018 | 1 50% | 721 36% | 0 0% | 248 12% | 0 0% | 725 36% | 1 50% | 314 16% |
| JUL-2018 | 3 60% | 723 36% | 0 0% | 243 12% | 0 0% | 717 36% | 2 40% | 314 16% |
| AUG-2018 | 2 100% | 715 36% | 0 0% | 238 12% | 0 0% | 716 36% | 0 0% | 308 16% |
| SEP-2018 | 6 100% | 707 36% | 0 0% | 236 12% | 0 0% | 712 36% | 0 0% | 311 16% |
| OCT-2018 | 3 60% | 695 35% | 0 0% | 234 12% | 0 0% | 710 36% | 2 40% | 323 16% |

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

| | bictegravir | | dolutegravir | | elvitegravir | | maraviroc | | raltegravir | | enfuvirtide | |
|----------|-------------|-------|--------------|----------|--------------|---------|-----------|-------|-------------|---------|-------------|------|
| | Initial | All | Initial | All | Initial | All | Initial | All | Initial | All | Initial | All |
| JAN-2017 | 0 0% | 0 0% | 13 81% | 1518 53% | 3 19% | 587 20% | 0 0% | 52 2% | 0 0% | 756 26% | 0 0% | 1 0% |
| FEB-2017 | 0 0% | 0 0% | 14 78% | 1560 54% | 4 22% | 588 20% | 0 0% | 48 2% | 0 0% | 732 25% | 0 0% | 1 0% |
| MAR-2017 | 0 0% | 0 0% | 13 87% | 1620 55% | 2 13% | 601 20% | 0 0% | 49 2% | 0 0% | 732 25% | 0 0% | 1 0% |
| APR-2017 | 0 0% | 0 0% | 14 78% | 1655 55% | 4 22% | 596 20% | 0 0% | 50 2% | 0 0% | 722 24% | 0 0% | 1 0% |
| MAY-2017 | 0 0% | 0 0% | 19 86% | 1726 57% | 3 14% | 602 20% | 0 0% | 47 2% | 0 0% | 715 23% | 0 0% | 1 0% |
| JUN-2017 | 0 0% | 0 0% | 12 75% | 1757 57% | 3 19% | 596 19% | 0 0% | 49 2% | 1 6% | 713 23% | 0 0% | 1 0% |
| JUL-2017 | 0 0% | 0 0% | 8 73% | 1791 58% | 3 27% | 592 19% | 0 0% | 48 2% | 0 0% | 705 23% | 0 0% | 1 0% |
| AUG-2017 | 0 0% | 0 0% | 13 72% | 1824 58% | 4 22% | 596 19% | 0 0% | 49 2% | 1 6% | 707 22% | 0 0% | 1 0% |
| SEP-2017 | 0 0% | 0 0% | 10 71% | 1833 58% | 4 29% | 600 19% | 0 0% | 50 2% | 0 0% | 700 22% | 0 0% | 1 0% |
| OCT-2017 | 0 0% | 0 0% | 8 89% | 1879 59% | 1 11% | 608 19% | 0 0% | 48 1% | 0 0% | 708 22% | 0 0% | 0 0% |
| NOV-2017 | 0 0% | 0 0% | 14 67% | 1939 60% | 5 24% | 611 19% | 0 0% | 49 2% | 2 10% | 701 22% | 0 0% | 0 0% |
| DEC-2017 | 0 0% | 0 0% | 11 69% | 1958 60% | 5 31% | 603 18% | 0 0% | 48 1% | 0 0% | 689 21% | 0 0% | 0 0% |
| JAN-2018 | 0 0% | 0 0% | 9 47% | 2006 60% | 8 42% | 631 19% | 0 0% | 46 1% | 2 11% | 688 21% | 0 0% | 0 0% |
| FEB-2018 | 0 0% | 0 0% | 16 70% | 2027 60% | 6 26% | 642 19% | 0 0% | 45 1% | 1 4% | 676 20% | 0 0% | 0 0% |
| MAR-2018 | 0 0% | 0 0% | 14 100% | 2061 61% | 0 0% | 645 19% | 0 0% | 43 1% | 0 0% | 674 20% | 0 0% | 0 0% |
| APR-2018 | 0 0% | 0 0% | 8 67% | 2106 61% | 4 33% | 654 19% | 0 0% | 44 1% | 0 0% | 681 20% | 0 0% | 0 0% |
| MAY-2018 | 0 0% | 0 0% | 13 65% | 2140 61% | 4 20% | 666 19% | 1 5% | 42 1% | 3 15% | 675 19% | 0 0% | 0 0% |
| JUN-2018 | 0 0% | 0 0% | 7 64% | 2175 62% | 3 27% | 675 19% | 0 0% | 42 1% | 1 9% | 678 19% | 0 0% | 0 0% |
| JUL-2018 | 0 0% | 0 0% | 7 58% | 2211 62% | 4 33% | 675 19% | 0 0% | 43 1% | 1 8% | 677 19% | 0 0% | 0 0% |
| AUG-2018 | 0 0% | 0 0% | 23 79% | 2259 62% | 5 17% | 675 19% | 0 0% | 42 1% | 1 3% | 671 19% | 0 0% | 0 0% |
| SEP-2018 | 0 0% | 9 0% | 5 36% | 2267 62% | 9 64% | 690 19% | 0 0% | 41 1% | 0 0% | 656 18% | 0 0% | 0 0% |
| OCT-2018 | 0 0% | 17 0% | 13 76% | 2317 63% | 4 24% | 707 19% | 0 0% | 40 1% | 0 0% | 660 18% | 0 0% | 0 0% |

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

| MON-YYYY | Boosted PI + 2 NRTIs | | NNRTI + 2 NRTIs | | Integrase + 2 NRTIs | | Un-boosted PI + 2 NRTIs | | MDRT | | Other | |
|----------|-------------------------|-------|--------------------|-------|------------------------|-------|----------------------------|------|------|------|-------|-------|
| | n | % | n | % | n | % | n | % | n | % | n | % |
| JAN-2017 | 2155 | 30.01 | 1793 | 24.97 | 2135 | 29.73 | 139 | 1.94 | 63 | 0.88 | 897 | 12.49 |
| FEB-2017 | 2125 | 29.79 | 1772 | 24.84 | 2165 | 30.35 | 133 | 1.86 | 55 | 0.77 | 884 | 12.39 |
| MAR-2017 | 2133 | 29.68 | 1754 | 24.41 | 2223 | 30.94 | 134 | 1.86 | 58 | 0.81 | 884 | 12.30 |
| APR-2017 | 2109 | 29.38 | 1744 | 24.30 | 2260 | 31.49 | 133 | 1.85 | 59 | 0.82 | 873 | 12.16 |
| MAY-2017 | 2108 | 29.18 | 1737 | 24.04 | 2308 | 31.95 | 132 | 1.83 | 59 | 0.82 | 880 | 12.18 |
| JUN-2017 | 2115 | 29.19 | 1719 | 23.73 | 2349 | 32.42 | 132 | 1.82 | 59 | 0.81 | 871 | 12.02 |
| JUL-2017 | 2102 | 29.03 | 1694 | 23.39 | 2386 | 32.95 | 130 | 1.80 | 62 | 0.86 | 867 | 11.97 |
| AUG-2017 | 2094 | 28.82 | 1687 | 23.22 | 2408 | 33.14 | 130 | 1.79 | 61 | 0.84 | 886 | 12.19 |
| SEP-2017 | 2074 | 28.72 | 1676 | 23.21 | 2427 | 33.61 | 127 | 1.76 | 57 | 0.79 | 861 | 11.92 |
| OCT-2017 | 2050 | 28.30 | 1674 | 23.11 | 2476 | 34.18 | 124 | 1.71 | 57 | 0.79 | 863 | 11.91 |
| NOV-2017 | 2003 | 27.67 | 1668 | 23.04 | 2519 | 34.79 | 119 | 1.64 | 56 | 0.77 | 875 | 12.09 |
| DEC-2017 | 1998 | 27.65 | 1660 | 22.97 | 2531 | 35.02 | 115 | 1.59 | 56 | 0.77 | 867 | 12.00 |
| JAN-2018 | 2010 | 27.56 | 1645 | 22.56 | 2595 | 35.58 | 117 | 1.60 | 55 | 0.75 | 871 | 11.94 |
| FEB-2018 | 1968 | 27.12 | 1630 | 22.46 | 2615 | 36.04 | 116 | 1.60 | 59 | 0.81 | 868 | 11.96 |
| MAR-2018 | 1979 | 27.19 | 1616 | 22.20 | 2647 | 36.36 | 113 | 1.55 | 56 | 0.77 | 868 | 11.92 |
| APR-2018 | 1938 | 26.68 | 1596 | 21.97 | 2698 | 37.14 | 114 | 1.57 | 58 | 0.80 | 861 | 11.85 |
| MAY-2018 | 1932 | 26.51 | 1575 | 21.61 | 2739 | 37.58 | 114 | 1.56 | 58 | 0.80 | 870 | 11.94 |
| JUN-2018 | 1913 | 26.23 | 1564 | 21.44 | 2791 | 38.26 | 113 | 1.55 | 58 | 0.80 | 855 | 11.72 |
| JUL-2018 | 1888 | 25.87 | 1567 | 21.47 | 2820 | 38.64 | 110 | 1.51 | 55 | 0.75 | 858 | 11.76 |
| AUG-2018 | 1867 | 25.58 | 1549 | 21.22 | 2866 | 39.26 | 111 | 1.52 | 56 | 0.77 | 851 | 11.66 |
| SEP-2018 | 1832 | 25.24 | 1533 | 21.12 | 2883 | 39.72 | 109 | 1.50 | 59 | 0.81 | 843 | 11.61 |
| OCT-2018 | 1851 | 25.22 | 1526 | 20.80 | 2943 | 40.11 | 104 | 1.42 | 54 | 0.74 | 860 | 11.72 |

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

| MON-YYYY | # of First Starts | # of Pts with CD4 < 100 | # of Pts with CD4: 100-199 | # of Pts with CD4: 200-349 | # of Pts with CD4: 350-500 | # of Pts with CD4 > 500 | Median CD4 |
|----------|-------------------|-------------------------|----------------------------|----------------------------|----------------------------|-------------------------|------------|
| JAN-2017 | 21 | 3 | 2 | 3 | 6 | 6 | 390 |
| FEB-2017 | 24 | 5 | 3 | 1 | 3 | 10 | 425 |
| MAR-2017 | 19 | 5 | 3 | 5 | 2 | 2 | 220 |
| APR-2017 | 20 | 1 | 2 | 6 | 5 | 5 | 350 |
| MAY-2017 | 22 | 2 | 0 | 3 | 9 | 8 | 405 |
| JUN-2017 | 24 | 6 | 2 | 5 | 3 | 7 | 230 |
| JUL-2017 | 14 | 2 | 2 | 2 | 1 | 5 | 340 |
| AUG-2017 | 25 | 4 | 0 | 4 | 3 | 12 | 510 |
| SEP-2017 | 16 | 1 | 2 | 3 | 3 | 5 | 440 |
| OCT-2017 | 6 | 2 | 0 | 0 | 2 | 2 | 435 |
| NOV-2017 | 19 | 2 | 1 | 6 | 3 | 7 | 430 |
| DEC-2017 | 18 | 2 | 2 | 4 | 4 | 5 | 390 |
| JAN-2018 | 12 | 1 | 1 | 0 | 4 | 4 | 470 |
| FEB-2018 | 27 | 3 | 2 | 2 | 6 | 13 | 485 |
| MAR-2018 | 21 | 4 | 1 | 5 | 4 | 6 | 325 |
| APR-2018 | 15 | 0 | 0 | 5 | 2 | 6 | 490 |
| MAY-2018 | 12 | 1 | 0 | 4 | 3 | 2 | 370 |
| JUN-2018 | 16 | 3 | 5 | 1 | 1 | 6 | 237 |
| JUL-2018 | 14 | 4 | 1 | 3 | 4 | 1 | 284 |
| AUG-2018 | 27 | 2 | 2 | 6 | 4 | 13 | 450 |
| SEP-2018 | 15 | 2 | 3 | 1 | 3 | 5 | 405 |
| OCT-2018 | 19 | 0 | 1 | 2 | 5 | 10 | 525 |

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

| MON-YYYY | # of Participants with PVL test | # of Participants with PVL test, and never on ART |
|----------|---------------------------------|---|
| JAN-2017 | 11553 | 3373 |
| FEB-2017 | 11578 | 3380 |
| MAR-2017 | 11629 | 3429 |
| APR-2017 | 11655 | 3444 |
| MAY-2017 | 11696 | 3469 |
| JUN-2017 | 11723 | 3483 |
| JUL-2017 | 11755 | 3513 |
| AUG-2017 | 11791 | 3540 |
| SEP-2017 | 11818 | 3565 |
| OCT-2017 | 11875 | 3619 |
| NOV-2017 | 11887 | 3618 |
| DEC-2017 | 11914 | 3624 |
| JAN-2018 | 11972 | 3666 |
| FEB-2018 | 12001 | 3680 |
| MAR-2018 | 12029 | 3709 |
| APR-2018 | 12059 | 3738 |
| MAY-2018 | 12094 | 3763 |
| JUN-2018 | 12106 | 3766 |
| JUL-2018 | 12134 | 3792 |
| AUG-2018 | 12148 | 3787 |
| SEP-2018 | 12173 | 3811 |
| OCT-2018 | 12197 | 3814 |

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
October 2018

N = 7338

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2018

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2018

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2018

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

October 2018

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

| HSDA | Age Group | Alive | Ever treated with ARVs | Currently treated with ARVs |
|------------------------------|--------------------|------------|------------------------|-----------------------------|
| EAST KOOTENAY | 20-34 | * | * | * |
| | 35-49 | * | * | * |
| | 50+ | * | * | * |
| | Total HSDA: | 40 | 53 | 24 |
| KOOTENAY BOUNDARY | 0-19 | * | * | * |
| | 20-34 | * | * | * |
| | 35-49 | * | * | * |
| | 50+ | * | * | * |
| Total HSDA: | 69 | 92 | 51 | |
| OKANAGAN | 0-19 | * | * | * |
| | 20-34 | * | * | * |
| | 35-49 | * | * | * |
| | 50+ | * | * | * |
| Total HSDA: | 357 | 479 | 267 | |
| THOMPSON/CARIBOO/ SHUSWAP | 0-19 | * | * | 0 |
| | 20-34 | * | * | 13 |
| | 35-49 | * | * | 39 |
| | 50+ | * | * | 84 |
| Total HSDA: | 187 | 249 | 136 | |
| Total HA: | | 653 | 873 | 478 |

| | Age Group | Alive | Ever treated with ARVs | Currently treated with ARVs |
|------------------|-----------|------------|------------------------|-----------------------------|
| | 0-19 | * | * | * |
| | 20-34 | * | * | * |
| | 35-49 | * | * | * |
| | 50+ | * | * | * |
| Total HA: | | 653 | 873 | 478 |

| Gender | Alive | Ever treated with ARVs | Currently treated with ARVs |
|--------|-------|------------------------|-----------------------------|
| Male | 513 | 693 | 380 |
| Female | 140 | 180 | 98 |

| Currently treated with ARVs | # of patients | Med Age | Med CD4 | Med PVL |
|-----------------------------|---------------|---------|---------|---------|
| Total HA: | 478 | 54 | 610 | 35 |

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
INTERIOR Health Authority**

| HSDA | Treatment Duration | Alive | Currently treated with ARVs |
|------------------------------|--------------------|------------|-----------------------------|
| EAST KOOTENAY | 10 years or more | 18 | * |
| | 5 years or more | 7 | * |
| | <5 years | 15 | * |
| | Total HSDA: | 40 | 24 |
| KOOTENAY BOUNDARY | 10 years or more | 42 | 30 |
| | 5 years or more | 14 | 11 |
| | <5 years | 13 | 10 |
| | Total HSDA: | 69 | 51 |
| OKANAGAN | 10 years or more | 220 | 158 |
| | 5 years or more | 57 | 46 |
| | <5 years | 80 | 63 |
| | Total HSDA: | 357 | 267 |
| THOMPSON/CARIBOO/ SHUSWAP | 10 years or more | 104 | 69 |
| | 5 years or more | 38 | 29 |
| | <5 years | 45 | 38 |
| | Total HSDA: | 187 | 136 |
| Total HA: | | 653 | 478 |

| | Treatment Duration | Alive | Currently treated with ARVs |
|------------------|--------------------|------------|-----------------------------|
| | 10 years or more | 384 | 268 |
| | 5 years or more | 116 | 88 |
| | <5 years | 153 | 122 |
| Total HA: | | 653 | 478 |

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

| HSDA of Physician Residency | # of Physicians ever prescribed ARVs | # of Patients ever treated by Physicians | # of Physicians currently prescribing ARVs | # of Patients currently treated by Physicians |
|-----------------------------|--------------------------------------|--|--|---|
| EAST KOOTENAY | 39 | 57 | 12 | 22 |
| KOOTENAY BOUNDARY | 66 | 119 | 20 | 42 |
| OKANAGAN | 210 | 788 | 63 | 280 |
| THOMPSON/CARIBOO/SHUSWAP | 126 | 484 | 36 | 137 |
| Total: | 441 | 1448 | 131 | 481 |

| HSDA of Patient Residency | # of Patients seeking Physician's care out of HA |
|---------------------------|--|
| EAST KOOTENAY | * |
| KOOTENAY BOUNDARY | * |
| OKANAGAN | * |
| THOMPSON/CARIBOO/SHUSWAP | * |
| Total: | 87 |

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

| HSDA | Age Group | Alive | Ever treated with ARVs | Currently treated with ARVs |
|------------------|--------------------|-------------|------------------------|-----------------------------|
| FRASER EAST | 0-19 | 5 | 5 | 5 |
| | 20-34 | 28 | 30 | 20 |
| | 35-49 | 110 | 122 | 81 |
| | 50+ | 211 | 282 | 169 |
| | Total HSDA: | 354 | 439 | 275 |
| FRASER NORTH | 0-19 | 10 | 10 | * |
| | 20-34 | 117 | 119 | * |
| | 35-49 | 348 | 383 | * |
| | 50+ | 532 | 841 | * |
| | Total HSDA: | 1007 | 1353 | 785 |
| FRASER SOUTH | 0-19 | 7 | 7 | 5 |
| | 20-34 | 109 | 111 | 78 |
| | 35-49 | 346 | 397 | 284 |
| | 50+ | 505 | 744 | 422 |
| | Total HSDA: | 967 | 1259 | 789 |
| Total HA: | | 2328 | 3051 | 1849 |

| | Age Group | Alive | Ever treated with ARVs | Currently treated with ARVs |
|------------------|-----------|-------------|------------------------|-----------------------------|
| | 0-19 | 22 | 22 | 12 |
| | 20-34 | 254 | 260 | 187 |
| | 35-49 | 804 | 902 | 632 |
| | 50+ | 1248 | 1867 | 1018 |
| Total HA: | | 2328 | 3051 | 1849 |

| Gender | Alive | Ever treated with ARVs | Currently treated with ARVs |
|--------|-------|------------------------|-----------------------------|
| Male | 1767 | 2342 | 1434 |
| Female | 561 | 709 | 415 |

| Currently treated with ARVs | # of patients | Med Age | Med CD4 | Med PVL |
|-----------------------------|---------------|---------|---------|---------|
| Total HA: | 1849 | 51 | 621 | 35 |

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

| HSDA | Treatment Duration | Alive | Currently treated with ARVs |
|------------------|--------------------|-------------|-----------------------------|
| FRASER EAST | 10 years or more | 189 | 143 |
| | 5 years or more | 95 | 76 |
| | <5 years | 70 | 56 |
| | Total HSDA: | 354 | 275 |
| FRASER NORTH | 10 years or more | 527 | 386 |
| | 5 years or more | 260 | 208 |
| | <5 years | 220 | 191 |
| | Total HSDA: | 1007 | 785 |
| FRASER SOUTH | 10 years or more | 496 | 396 |
| | 5 years or more | 233 | 188 |
| | <5 years | 238 | 205 |
| | Total HSDA: | 967 | 789 |
| Total HA: | | 2328 | 1849 |

| Treatment Duration | Alive | Currently treated with ARVs |
|--------------------|-------------|-----------------------------|
| 10 years or more | 1212 | 925 |
| 5 years or more | 588 | 472 |
| <5 years | 528 | 452 |
| Total HA: | 2328 | 1849 |

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

| HSDA of Physician Residency | # of Physicians ever prescribed ARVs | # of Patients ever treated by Physicians | # of Physicians currently prescribing ARVs | # of Patients currently treated by Physicians |
|-----------------------------|--------------------------------------|--|--|---|
| FRASER EAST | 137 | 481 | 36 | 72 |
| FRASER NORTH | 246 | 1530 | 57 | 248 |
| FRASER SOUTH | 210 | 1311 | 45 | 354 |
| Total: | 593 | 3322 | 138 | 674 |

| HSDA of Patient Residency | # of Patients seeking Physician's care out of HA |
|---------------------------|--|
| FRASER EAST | 195 |
| FRASER NORTH | 659 |
| FRASER SOUTH | 535 |
| Total: | 1389 |

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

| HSDA | Age Group | Alive | Ever treated with ARVs | Currently treated with ARVs |
|---------------------------------|--------------------|-------------|------------------------|-----------------------------|
| NORTH SHORE/ COAST GARIBALDI | 0-19 | * | * | 0 |
| | 20-34 | * | * | 18 |
| | 35-49 | * | * | 71 |
| | 50+ | * | * | 194 |
| | Total HSDA: | | 329 | 474 |
| RICHMOND | 0-19 | * | * | * |
| | 20-34 | * | * | * |
| | 35-49 | * | * | * |
| | 50+ | * | * | * |
| | Total HSDA: | | 165 | 214 |
| VANCOUVER | 0-19 | 36 | 39 | 6 |
| | 20-34 | 433 | 445 | 318 |
| | 35-49 | 1449 | 1634 | 1070 |
| | 50+ | 2711 | 4604 | 2072 |
| | Total HSDA: | 4629 | 6722 | 3466 |
| Total HA: | | 5123 | 7410 | 3877 |

| | Age Group | Alive | Ever treated with ARVs | Currently treated with ARVs |
|------------------|-----------|-------------|------------------------|-----------------------------|
| | 0-19 | 39 | 42 | 7 |
| | 20-34 | 483 | 496 | 354 |
| | 35-49 | 1578 | 1776 | 1177 |
| | 50+ | 3023 | 5096 | 2339 |
| Total HA: | | 5123 | 7410 | 3877 |

| Gender | Alive | Ever treated with ARVs | Currently treated with ARVs |
|--------|-------|------------------------|-----------------------------|
| | 2 | 2 | 0 |
| Male | 4503 | 6499 | 3418 |
| Female | 618 | 909 | 459 |

| Currently treated with ARVs | # of patients | Med Age | Med CD4 | Med PVL |
|-----------------------------|---------------|---------|---------|---------|
| Total HA: | 3877 | 53 | 630 | 35 |

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

| HSDA | Treatment Duration | Alive | Currently treated with ARVs |
|---------------------------------|--------------------|-------------|-----------------------------|
| NORTH SHORE/ COAST GARIBALDI | 10 years or more | 177 | 147 |
| | 5 years or more | 78 | 67 |
| | <5 years | 74 | 69 |
| | Total HSDA: | 329 | 283 |
| RICHMOND | 10 years or more | 85 | 63 |
| | 5 years or more | 41 | 32 |
| | <5 years | 39 | 33 |
| | Total HSDA: | 165 | 128 |
| VANCOUVER | 10 years or more | 2589 | 1863 |
| | 5 years or more | 1193 | 906 |
| | <5 years | 847 | 697 |
| | Never on ART | 0 | 0 |
| | Total HSDA: | 4629 | 3466 |
| Total HA: | 5123 | 3877 | |

| | Treatment Duration | Alive | Currently treated with ARVs |
|------------------|--------------------|-------------|-----------------------------|
| | 10 years or more | 2851 | 2073 |
| | 5 years or more | 1312 | 1005 |
| | <5 years | 960 | 799 |
| | Never on ART | 0 | 0 |
| Total HA: | | 5123 | 3877 |

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

| HSDA of Physician Residency | # of Physicians ever prescribed ARVs | # of Patients ever treated by Physicians | # of Physicians currently prescribing ARVs | # of Patients currently treated by Physicians |
|-----------------------------|--------------------------------------|--|--|---|
| NORTH SHORE/COAST GARIBALDI | 165 | 483 | 55 | 178 |
| RICHMOND | 43 | 280 | 13 | 91 |
| VANCOUVER | 582 | 10614 | 203 | 5360 |
| Total: | 790 | 11377 | 271 | 5629 |

| HSDA of Patient Residency | # of Patients seeking Physician's care out of HA |
|-----------------------------|--|
| NORTH SHORE/COAST GARIBALDI | * |
| RICHMOND | * |
| VANCOUVER | * |
| Total: | 117 |

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

| HSDA | Age Group | Alive | Ever treated with ARVs | Currently treated with ARVs |
|--------------------------|--------------------|-------------|------------------------|-----------------------------|
| CENTRAL VANCOUVER ISLAND | 0-19 | * | * | * |
| | 20-34 | * | * | * |
| | 35-49 | * | * | * |
| | 50+ | * | * | * |
| | Total HSDA: | | 309 | 435 |
| NORTH VANCOUVER ISLAND | 0-19 | * | * | * |
| | 20-34 | * | * | * |
| | 35-49 | * | * | * |
| | 50+ | * | * | * |
| | Total HSDA: | | 120 | 159 |
| SOUTH VANCOUVER ISLAND | 0-19 | * | * | * |
| | 20-34 | * | * | * |
| | 35-49 | * | * | * |
| | 50+ | * | * | * |
| | Total HSDA: | | 711 | 1004 |
| Total HA: | | 1140 | 1598 | 884 |

| | Age Group | Alive | Ever treated with ARVs | Currently treated with ARVs |
|------------------|-----------|-------------|------------------------|-----------------------------|
| | 0-19 | 7 | 7 | * |
| | 20-34 | 102 | 108 | * |
| | 35-49 | 300 | 349 | * |
| | 50+ | 731 | 1134 | * |
| Total HA: | | 1140 | 1598 | 884 |

| Gender | Alive | Ever treated with ARVs | Currently treated with ARVs |
|--------|-------|------------------------|-----------------------------|
| Male | 939 | 1316 | 739 |
| Female | 201 | 282 | 145 |

| Currently treated with ARVs | # of patients | Med Age | Med CD4 | Med PVL |
|-----------------------------|---------------|---------|---------|---------|
| Total HA: | 884 | 54 | 520 | 35 |

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

| HSDA | Treatment Duration | Alive | Currently treated with ARVs |
|--------------------------|--------------------|-------------|-----------------------------|
| CENTRAL VANCOUVER ISLAND | 10 years or more | 161 | 132 |
| | 5 years or more | 73 | 60 |
| | <5 years | 75 | 59 |
| | Total HSDA: | 309 | 251 |
| NORTH VANCOUVER ISLAND | 10 years or more | 64 | 53 |
| | 5 years or more | 33 | 25 |
| | <5 years | 23 | 17 |
| | Total HSDA: | 120 | 95 |
| SOUTH VANCOUVER ISLAND | 10 years or more | 398 | 278 |
| | 5 years or more | 155 | 127 |
| | <5 years | 158 | 133 |
| | Total HSDA: | 711 | 538 |
| Total HA: | | 1140 | 884 |

| | Treatment Duration | Alive | Currently treated with ARVs |
|------------------|--------------------|-------------|-----------------------------|
| | 10 years or more | 623 | 463 |
| | 5 years or more | 261 | 212 |
| | <5 years | 256 | 209 |
| Total HA: | | 1140 | 884 |

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

| HSDA of Physician Residency | # of Physicians ever prescribed ARVs | # of Patients ever treated by Physicians | # of Physicians currently prescribing ARVs | # of Patients currently treated by Physicians |
|-----------------------------|--------------------------------------|--|--|---|
| CENTRAL VANCOUVER ISLAND | 189 | 831 | 75 | 192 |
| NORTH VANCOUVER ISLAND | 127 | 257 | 40 | 70 |
| SOUTH VANCOUVER ISLAND | 204 | 1729 | 43 | 556 |
| Total: | 520 | 2817 | 158 | 818 |

| HSDA of Patient Residency | # of Patients seeking Physician's care out of HA |
|---------------------------|--|
| CENTRAL VANCOUVER ISLAND | 50 |
| NORTH VANCOUVER ISLAND | 35 |
| SOUTH VANCOUVER ISLAND | 104 |
| Total: | 189 |

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

| HSDA | Age Group | Alive | Ever treated with ARVs | Currently treated with ARVs |
|-------------------|--------------------|------------|------------------------|-----------------------------|
| NORTH EAST | 0-19 | * | * | * |
| | 20-34 | * | * | * |
| | 35-49 | * | * | * |
| | 50+ | * | * | * |
| | Total HSDA: | | 39 | 47 |
| NORTH WEST | 0-19 | * | * | 0 |
| | 20-34 | * | * | 9 |
| | 35-49 | * | * | 12 |
| | 50+ | * | * | 30 |
| | Total HSDA: | | 68 | 106 |
| NORTHERN INTERIOR | 0-19 | 5 | 5 | * |
| | 20-34 | 17 | 20 | * |
| | 35-49 | 72 | 88 | * |
| | 50+ | 85 | 141 | * |
| | Total HSDA: | | 179 | 254 |
| Total HA: | | 286 | 407 | 209 |

| | Age Group | Alive | Ever treated with ARVs | Currently treated with ARVs |
|------------------|-----------|------------|------------------------|-----------------------------|
| | 0-19 | 7 | 7 | * |
| | 20-34 | 31 | 36 | * |
| | 35-49 | 108 | 143 | * |
| | 50+ | 140 | 221 | * |
| Total HA: | | 286 | 407 | 209 |

| Gender | Alive | Ever treated with ARVs | Currently treated with ARVs |
|--------|-------|------------------------|-----------------------------|
| Male | 174 | 251 | 128 |
| Female | 112 | 156 | 81 |

| Currently treated with ARVs | # of patients | Med Age | Med CD4 | Med PVL |
|-----------------------------|---------------|---------|---------|---------|
| Total HA: | 209 | 50 | 550 | 35 |

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

| HSDA | Treatment Duration | Alive | Currently treated with ARVs |
|-------------------|--------------------|------------|-----------------------------|
| NORTH EAST | 10 years or more | 17 | 8 |
| | 5 years or more | 14 | 9 |
| | <5 years | 8 | 5 |
| | Total HSDA: | 39 | 22 |
| NORTH WEST | 10 years or more | 27 | 17 |
| | 5 years or more | 28 | 24 |
| | <5 years | 13 | 10 |
| | Total HSDA: | 68 | 51 |
| NORTHERN INTERIOR | 10 years or more | 67 | 47 |
| | 5 years or more | 65 | 52 |
| | <5 years | 47 | 37 |
| | Total HSDA: | 179 | 136 |
| Total HA: | | 286 | 209 |

| | Treatment Duration | Alive | Currently treated with ARVs |
|------------------|--------------------|------------|-----------------------------|
| | 10 years or more | 111 | 72 |
| | 5 years or more | 107 | 85 |
| | <5 years | 68 | 52 |
| Total HA: | | 286 | 209 |

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

| HSDA of Physician Residency | # of Physicians ever prescribed ARVs | # of Patients ever treated by Physicians | # of Physicians currently prescribing ARVs | # of Patients currently treated by Physicians |
|-----------------------------|--------------------------------------|--|--|---|
| NORTH EAST | 37 | 61 | 8 | 9 |
| NORTH WEST | 69 | 156 | 16 | 28 |
| NORTHERN INTERIOR | 103 | 444 | 14 | 187 |
| Total: | 209 | 661 | 38 | 224 |

| HSDA of Patient Residency | # of Patients seeking Physician's care out of HA |
|---------------------------|--|
| NORTH EAST | 6 |
| NORTH WEST | 19 |
| NORTHERN INTERIOR | 15 |
| Total: | 40 |

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

| HA | HSDA | Alive | Ever treated with ARVs | Currently treated with ARVs |
|-------------------|-----------------------------|------------|------------------------|-----------------------------|
| INTERIOR | EAST KOOTENAY | 6 | 10 | * |
| | KOOTENAY BOUNDARY | 6 | 9 | * |
| | OKANAGAN | 22 | 37 | * |
| | THOMPSON/CARIBOO/SHUSWAP | 25 | 43 | * |
| | Total HA: | 59 | 99 | 43 |
| FRASER | FRASER EAST | 39 | 49 | 31 |
| | FRASER NORTH | 55 | 91 | 47 |
| | FRASER SOUTH | 72 | 104 | 54 |
| | Total HA: | 166 | 244 | 132 |
| VANCOUVER COASTAL | NORTH SHORE/COAST GARIBALDI | 25 | 48 | 23 |
| | RICHMOND | 11 | 16 | 10 |
| | VANCOUVER | 495 | 840 | 401 |
| | Total HA: | 531 | 904 | 434 |
| VANCOUVER ISLAND | CENTRAL VANCOUVER ISLAND | 49 | 77 | 39 |
| | NORTH VANCOUVER ISLAND | 16 | 25 | 13 |
| | SOUTH VANCOUVER ISLAND | 34 | 76 | 25 |
| | Total HA: | 99 | 178 | 77 |
| NORTHERN | NORTH EAST | 9 | 11 | 8 |
| | NORTH WEST | 32 | 61 | 26 |
| | NORTHERN INTERIOR | 62 | 98 | 51 |
| | Total HA: | 103 | 170 | 85 |
| Total: | | 958 | 1595 | 771 |

| Gender | Alive | Ever treated with ARVs | Currently treated with ARVs |
|--------|-------|------------------------|-----------------------------|
| Male | 598 | 1018 | 480 |
| Female | 360 | 577 | 291 |

| Currently treated with ARVs | # of patients | Med Age | Med CD4 | Med PVL |
|-----------------------------|---------------|---------|---------|---------|
| Total: | 771 | 51 | 500 | 35 |

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by





blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

